RIO’s Prof Sarah Fidler featured in a news piece celebrating 25 years of Imperial’s Faculty of Medicine and trailblazing HIV and AIDS research

1st Dec 2022 by Genevieve Timmins, Imperial College London The launch of Imperial’s Faculty of Medicine in 1997 coincided with a new era in HIV/AIDS treatment and research. Just prior to its creation came the groundbreaking revelation that combining three antiretroviral drugs could drastically improve the prognosis of people living with HIV. The subsequent rollout […]

Read More…

Long-awaited results of the eCLEAR study are out showing the impact of the bNAb ‘3BNC117’ in people with detectable viraemia

17 Oct 2022, Nature Medicine The eCLEAR study published their results in Nature Medicine in October. This study combined the use of 3BNC117, which is a broadly neutralising antibody (bNAb), with a potent latency reversing agent, romidepsin, to reduce the HIV reservoir in individuals starting antiretroviral treatment (ART) for the first time. The study was […]

Read More…

Nature publication: antibody therapy controls HIV for months in new clinical trial

Findings from a clinical trial led by Rockefeller University scientists as reported by journal Nature highlight anti-HIV antibodies as a novel treatment option; one that wouldn’t rely on vigilant daily dosing and could potentially reduce the body’s reservoir of HIV, which conventional antiretroviral drugs cannot do. Read the full article here […]

Read More…

RIO trial update

We are delighted to note that we are currently recruiting in all 7 clinical sites across London and Brighton and will shortly be opening 3 new sites at St George’s Hospital in London, Western General Hospital in Edinburgh and North Manchester General Hospital. To date we have recruited and dosed 20 participants into the study. […]

Read More…